Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

Medscape Medical News, May 16, 2019 Alert European Commission OKs Dupilumab for Severe Asthma Dupilumab is for patients with moderate-to-severe asthma and increased blood eosinophil and/or raised ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Exacerbations fell with omalizumab and mepolizumab for patients with asthma and obesity. Obesity did not decrease dupilumab’s rate of response in treating asthma. Tezepelumab may address type 2 ...

The committee concluded that dupilumab does not represent a cost-effective use of resources, so could not be recommended for treating severe asthma with type 2 inflammation.

such as asthma, allergic rhinitis or food allergies. Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Further information NICE will not progress with an appraisal for this indication due to positive guidance in the adult population within TA751. NHS England and Improvement will commission treatments ...

Further information NICE will not progress with an appraisal for this indication due to positive guidance in the adult population within TA751. NHS England and Improvement will commission treatments ...